Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › IMCR

Immunocore

IMCR Lead: Approved 1 Biotech Distilled article ↓
DermatologyInfectious DiseaseMetabolicOncology Protein

Most recent annual filing: 2026-02-25

Catalyst timeline

9 trackedQuarter catalyst calendar →
  1. Brenetafusp Ph1 readout2H 2026Brenetafusp Ph1 readout, 2H 2026, notable
  2. IMC-P115C Ph1 interim2H 2026IMC-P115C Ph1 interim, 2H 2026, notable
  3. IMC-U120AI IND filing2H 2026IMC-U120AI IND filing, 2H 2026, notable
  4. Tebentafusp TEBE-AM toplineas early as the end of 2026Tebentafusp TEBE-AM topline, as early as the end of 2026, thesis-defining
  5. Immatics anzu-cel SUPRAME topline1H 2027Immatics anzu-cel SUPRAME topline, 1H 2027, major
  6. IMC-M113V HIV Ph1 readout1H 2027IMC-M113V HIV Ph1 readout, 1H 2027, notable
  7. IMC-R117C PIWIL1-A02 Ph1 interim2027IMC-R117C PIWIL1-A02 Ph1 interim, 2027, notable
  8. PRISM-MEL-301 / ATOM corporate update2027PRISM-MEL-301 / ATOM corporate update, 2027, routine
  9. ATOM enrollment done2028ATOM enrollment done, 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Technology platforms

ImmTAX

Immune mobilizing monoclonal TCRs Against X disease — modular bispecific TCR platform combining high-affinity engineered TCR targeting system with tailored effector functions (anti-CD3 for immune activation or PD1 agonist for immune suppression); broad disease focus across oncology, infectious diseases, and autoimmune diseases

ImmTAC

Immune mobilizing monoclonal TCRs Against Cancer — oncology sub-platform of ImmTAX; bispecific soluble TCR molecules with anti-CD3 effector for T cell recruitment and activation; focus on solid tumors including melanoma, ovarian, lung, and colorectal cancers

Targets: CD3

ImmTAV

Immune mobilizing monoclonal TCRs Against Viruses — infectious disease sub-platform of ImmTAX; bispecific soluble TCR molecules with high specificity for low-expression viral antigens combined with anti-CD3 effector; focus on HIV and HBV functional cure

Targets: CD3

ImmTAAI

Immune modulating monoclonal TCRs Against AutoImmune disease — autoimmune sub-platform of ImmTAX; generates precision tissue-specific immune downmodulation via PD1 receptor agonism; focus on autoimmune diseases including type 1 diabetes and atopic dermatitis

Targets: PD1

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.